Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To determine long-term efficacy and safety of an extended macular vision intraocular lens (IOL) implanted in patients with dry age-related macular degeneration (AMD) and visually insignificant cataracts.

Design: Retrospective observational case series.

Setting: MicroChirurgia Oculare, Italy.

Methods: A retrospective case series of patients with dry AMD and visually insignificant cataracts undergoing phacoemulsification and implantation of an extended macular vision IOL designed to optimize image quality up to 10° from the foveal center (EyeMax Mono, Sharpview Ophthalmology, London, UK). Criteria for implantation were visually insignificant cataract (NC1 according to LOCS III classification) with dry age-related macular degeneration. Hypermetropia was targeted in most eyes to provide magnification when corrected with spectacles. Primary outcome measures were changes in corrected distant and secondary outcome measures included near visual acuity (CDVA and CNVA, respectively) between baseline and latest follow-up and safety outcomes.

Results: 113 eyes of 86 patients (mean age 70.3±7.9 years) were included (mean follow-up: 48.3±25.1 months). Mean CDVA improved by 0.22 logMAR (11 ETDRS letters), from 0.53±0.4 to 0.31±0.3 (n=113, p<0.001). Similarly, mean CNVA improved by 0.08 logMAR (4 ETDRS letters), from 0.45±0.2 to 0.37±0.2 (n=77, p<0.001). Eleven eyes had AMD with extensive atrophy, and their mean CDVA improved by 0.32 logMAR (16 ETDRS letters). Three eyes (2.7%) experienced loss of more than one line in logMAR CDVA and four eyes (5.2%) experienced loss of more than one line in logMAR CNVA. No complications or instances of IOL exchange were reported.

Conclusion: Visual improvement in eyes with visually insignificant cataract and AMD who underwent phacoemulsification and were implanted with EyeMax Mono IOL appears to be influenced by the IOL optical design. Vision enhancement in eyes with visually insignificant cataracts underscores the IOL's ability to optimize use of healthy retinal areas. Prospective studies with control groups are needed to confirm these findings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461591PMC
http://dx.doi.org/10.2147/OPTH.S481570DOI Listing

Publication Analysis

Top Keywords

visually insignificant
16
extended macular
12
macular vision
12
vision iol
8
insignificant cataract
8
patients dry
8
dry age-related
8
age-related macular
8
macular degeneration
8
amd visually
8

Similar Publications

Establishing next-generation reference intervals for pro-gastrin-releasing peptide using a dynamic modeling approach.

J Transl Med

September 2025

Department of Laboratory Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, 102218, China.

Background: Serum pro-gastrin-releasing peptide (ProGRP) levels significantly vary with age. However, conventional partitioned reference intervals (RIs) fail to reflect the continuous and subtle physiological changes associated with aging. To address this limitation, we investigated the age- and sex-specific dynamics of ProGRP levels and innovatively developed next-generation RIs for adults and elderly individuals in North China.

View Article and Find Full Text PDF

Evaluation of deep learning models using explainable AI with qualitative and quantitative analysis for rice leaf disease detection.

Sci Rep

August 2025

Department of Computer Science and Engineering, Vignan's Foundation for Science, Technology, and Research, Guntur, 522213, Andhra Pradesh, India.

Deep learning models have shown remarkable success in disease detection and classification tasks, but lack transparency in their decision-making process, creating reliability and trust issues. Although traditional evaluation methods focus entirely on performance metrics such as classification accuracy, precision and recall, they fail to assess whether the models are considering relevant features for decision-making. The main objective of this work is to develop and validate a comprehensive three-stage methodology that combines conventional performance evaluation with qualitative and quantitative evaluation of explainable artificial intelligence (XAI) visualizations to assess both the accuracy and reliability of deep learning models.

View Article and Find Full Text PDF

Background: The precise differentiation of recurrent glioma from treatment-related changes, such as pseudoprogression or radiation necrosis, is essential for treatment planning and remains a significant challenge. Fibroblast activation protein (FAP) expressed by cancer-associated fibroblasts can be targeted with PET tracers for in vivo visualization and quantification. This study aims to evaluate the diagnostic and prognostic effectiveness of FAP expression in patients with potential recurrent glioma by directly comparing [gallium-68] FAP inhibitor-04 and [fluorine-18] fluoroethyl-L-tyrosine PET/CT imaging.

View Article and Find Full Text PDF

Study Design: Retrospective study.

Objectives: To assess the radiological, clinical, and neurological outcome of patients who had thoracolumbar burst fractures and had undergone short-segment posterior stabilization with single-index screw (SIS) or double-index screws (DIS) at the fractured vertebra.

Methods: We included patients with AO type A and B with thoracolumbar injury classification and severity score (TLICS) ≥ 5, load-sharing classification (LSC) score ≥ 7, and a follow-up period of more than 2 years.

View Article and Find Full Text PDF

A new accommodative sulcus-based intraocular lens, two years follow-up clinical observations and complications.

Asia Pac J Ophthalmol (Phila)

August 2025

Vissum Grupo Miranza, Alicante, Spain; Division of Ophthalmology, Universidad Miguel Hernández, Alicante, Spain. Electronic address:

Purpose: To report the clinical outcome, observations and complications related to the sulcus implantations of a new accommodative intraocular lens, the Lumina (AkkoLens Clinical b.v., Breda, The Netherlands) along the twenty-four-month period.

View Article and Find Full Text PDF